Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...
Gilead Sciences said on Monday its experimental HIV treatment met the main goal and was found to be statistically ...
Investigational Treatment Regimen Could Expand Options for Virologically Suppressed Adults –– Positive Phase 3 Results from ...
Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.
Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...
Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...
Choose San Francisco Business Times as a preferred news source to see more of our reporting on Google. It is the first work ...
By Dana PiccoliNEWS IS OUT The Choose U World AIDS Day panel brought together three longtime advocates living with HIV to ...
Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue ...
News Medical on MSN
Chemotherapy may reduce HIV-infected T cells
Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people living with HIV to lead long, productive lives and keep the virus in check at ...
An updated Canadian guideline on HIV prevention addresses the expanding range of medications available to reduce the risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback